In an oral session at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, Christopher Sweeney, MBBS, DHS, FRACP, director of the South Australian Immunogenomics Cancer Institute (SAiGENCI) of Adelaide University, Australia, discussed optimal treatment selection for patients with metastatic hormone-sensitive prostate cancer (HSPC).1 Specifically, he highlighted 4 major points when focusing on treatment for these patients:
- Harnessing investigator-generated data through industry and investigator-sponsored trials
- Acknowledging selective benefit with maximal dosing
- Leveraging companion diagnostics, despite difficulty, to minimize futile toxic therapy
- Realizing near-term benefit with personalized precision medicine through biomarker-directed treatment selection
“[This presentation] is timely…